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the viability of rat β-cells from two 
sources—an insulinoma cell line and 
islets. Then, by inhibiting NO synthesis 
or by adding an NO donor, they provide 
evidence that IL-1-induced death 
of β-cells is mediated in part by NO 
production. Turning to the mechanism 
of β-cell death, the researchers show that 
IL-1 treatment failed to activate caspase 
3—an enzyme required for apoptosis—in 
β-cells, and that a caspase-3 inhibitor 
did not attenuate IL-1 induced β-cell 
death. Another marker of apoptotic cell 
death—lipid accumulation on the cell 
surface—was also missing in β-cells 
treated with IL-1.
Having discounted death by apoptosis, 
the researchers then show that IL-1 
stimulated the release of HMGB1 (a 
chromatin-binding protein that is 
released by cells undergoing necrosis 
but not apoptosis) by rat β-cells. 
Finally, because human β-cells behave 
somewhat differently from rat β-cells, 
the researchers demonstrate that a 
combination of cytokines (including IL-1) 
stimulated HMGB1 release from some 
preparations of human islets in an NO-
dependent manner.
Overall, the authors conclude that 
macrophage-derived cytokines may 
participate in the early stages of type 1 
diabetes by inducing necrotic death in 
β-cells. Other researchers believe that 
apoptotic cell death is more important 
in these early stages, particularly in 
human cells. But, based on their results, 
Corbett and colleagues speculate that 
cytokine induction of necrosis could 
kick start type 1 diabetes by causing 
the release of both β-cell antigens and 
HMGB1, which stimulates inﬂ  ammatory 
responses. Although these ﬁ  ndings need 
to be conﬁ  rmed within the context of 
the human pancreas—what cells do in 
vitro may not reﬂ  ect what happens in the 
body—they provide new insights into 
the early stages of type 1 diabetes that 
could suggest ways to prevent or stop its 
development.
Steer SA, Scarim AL, Chambers KT, Corbett 
JA (2006) Interleukin-1 stimulates β-cell 
necrosis and release of the immmunological 
adjuvant HMGB1. DOI: 10.1371/journal.
pmed.0030017
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Diabetes mellitus is a major global 
health problem. The most common form 
of diabetes—90%–95% of cases—is 
type 2 or non-insulin-dependent 
diabetes, which affects mainly adults. 
The remaining cases are type 1 or 
insulin-dependent diabetes. Also known 
as juvenile diabetes, type 1 diabetes 
usually develops before the age of 30. 
It is an autoimmune disease in which 
the insulin-producing or β-cells of 
the pancreatic islets of Langerhans 
(groups of specialized cells that regulate 
blood sugar levels) are destroyed by 
lymphocytes. Type 1 diabetes affects 
about one in 500 American children and 
adolescents; the only treatment is daily 
insulin injections.
β-cell death is the hallmark of type 1 
diabetes. An early phase of β-cell death, 
probably triggered by environmental 
factors (for example, viral infection) 
in genetically susceptible individuals, 
releases β-cell-speciﬁ  c antigens; 
subsequently, T lymphocytes that 
speciﬁ  cally recognize these antigens 
mediate widespread β-cell killing. John 
Corbett and colleagues believe that by 
studying the early phase of β-cell death, 
it may be possible to ﬁ  nd ways to prevent 
this destructive autoimmunity from 
developing in individuals with a family 
history of type 1 diabetes.
Cytokines, chemical messengers 
produced by lymphocytes and 
macrophages, are thought to contribute 
to the loss of β-cell function and viability 
early in autoimmune diabetes. The 
effect of cytokines on β-cell function is 
mediated by nitric oxide (NO), but it is not 
clear if the same is true for β-cell death. In 
their study, Corbett and colleagues asked 
whether NO mediates the death of rat β-
cells induced in vitro by the macrophage-
derived cytokine interleukin-1 (IL-1), and 
whether the cells are killed by apoptosis 
or necrosis, two different mechanisms of 
cell death. Apoptosis, or programmed cell 
death, is a highly organized process that 
minimizes the leakage of cell contents 
and the development of inﬂ  ammation. 
Necrosis is much less tidy: the dying cells 
swell and burst, releasing their contents 
into the extracellular space where they 
cause inﬂ  ammation.
The researchers report that 24–48 
hours treatment with IL-1 reduced 
Death by Necrosis: The Early Stages of Type 1 Diabetes
DOI: 10.1371/journal.pmed.0030051 
DOI: 10.1371/journal.pmed.0030051.g001
IL-1 causes nuclear membrane breakdown 
in rat insulinoma cells
Misfolding of a single protein, the 
cellular prion protein (PrPc) into the 
disease-associated form PrPSc is believed 
to cause fatal prion diseases in humans 
and other mammals, including sheep, 
cattle, and deer. The misfolding can occur 
sporadically or after contact—through 
inoculation or ingestion—with PrPSc 
from an external source. There are also 
familial forms of prion diseases that are 
associated with certain mutations in 
PNRP, the gene encoding PrPc. These 
abnormal PrPc proteins are thought to 
have a higher probability to misfold 
than normal PrPc. The idea is that a few 
misfolded molecules can initiate a chain 
reaction and cause transformation of 
many of the other PrPc molecules into 
harmful PrPSc versions. The presence 
of PrPSc proteins causes widespread 
cell death, leading to the characteristic 
spongiform degeneration of the brain 
that kills patients, most of them within a 
matter of months. 
The most common human prion 
disease is sporadic Creutzfeld  –Jacob 
Disease (sCJD). The disease is rare 
(affecting roughly one to two individuals 
per a million people, worldwide), and its 
etiology is unclear; neither exogenous 
nor endogenous causes have been 
identiﬁ  ed. sCJD is inevitably fatal, but the 
disease is clinically, pathologically, and 
genetically heterogeneous. Most patients 
Toward a Better Understanding of Human Prion Diseases
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have rapidly progressing dementia, 
often accompanied by involuntary 
muscle spasms, and death occurs within 
months of the ﬁ  rst clinical symptoms. 
However, for some patients ataxia is the 
ﬁ  rst clinical sign, while others develop 
sight problems, and for some the 
disease duration can be more than two 
years. In the hope that understanding 
the heterogeneity will help them 
to understand what causes sCJD, 
researchers are trying to systematically 
collect and catalog data from patients. To 
do this in a meaningful way, standardized 
assays that allow results from different 
patients and different laboratories to 
be compared in a meaningful way are 
necessary. 
Markus Glatzel and colleagues have 
developed such an assay, and applied 
it as part of the detailed molecular 
characterization to autopsy samples 
from 50 patients with sCJD. The new 
assay, which the researchers call PrPSc 
proﬁ  ling, measures the amount of 
PrPSc in deﬁ  ned brain regions. In the 
past, PrPSc amounts were routinely 
only measured in one or two regions 
by a variety of assays. PrPSc proﬁ  ling 
quantiﬁ  es the amount of PrPSc in nine 
deﬁ  ned brain regions relative to internal 
standards, and thereby allows for direct 
comparison of individual proﬁ  les. 
The researchers determined PrPSc 
proﬁ  les of 50 patients, and tried to 
correlate the proﬁ  les with information 
on disease types of the patients and 
prion types present in the different 
brain areas. sCJD types are determined 
by a patients’  PRNP genotype at the 
polymorphic position 129 of PRNP and 
by the relative resistance of PrPSc to 
proteolytic degradation. It is thought 
that most patients only have one prion 
type, but previous reports have described 
coexistence of two different types in 
some samples. 
Analysis of this wealth of data revealed 
correlations between distinct PrPSc 
distribution patterns and sCJD subtypes. 
These results have implications for 
conﬁ  rmation of sCJD by brain biopsy. 
Before doing such biopsies, Glatzel and 
colleagues suggest, the sCJD subtype 
should be determined so that the 
correct brain area is examined. The 
researchers also found coexistence of 
two different prion types in 20% of their 
overall samples, and in more than 50% 
of the samples from patients who were 
heterozygous for the 129 polymorphism 
in the PRNP gene. These data lend further 
support to a link between molecular 
signature and clinical heterogeneity of 
the disease. 
While many questions remain, this 
study underlines that the systematic 
analysis of prion cases can reveal links 
between molecular pathology, genetic 
makeup of patients, and disease 
symptoms. Glatzel and colleagues believe 
that “PrPSc proﬁ  ling will be a valuable tool 
for prion research.” In the hope that it will 
“facilitate comparisons of PrPSc quantities 
present in deﬁ  ned samples,” the 
researchers will make their PrPSc standard 
available to the scientiﬁ  c community. 
Schoch G, Seeger H, Bogousslavsky J, 
Tolnay M, Janzer RC, et al. (2006) Analysis 
of prion strains by PrPSc proﬁ  ling in 
sporadic Creutzfeldt–Jakob disease. DOI: 
10.1371/journal.pmed.0030014
DOI: 10.1371/journal.pmed.0030055.g001
PrPSc proﬁ  ling was done in nine different central nervous system areas
Some of the biggest public health successes in the Western 
world have come about because of simple records of people’s 
deaths—their age at death, where they lived, and what they 
died of. Soaring lung cancer rates in the United Kingdom and 
United States around World War II, for example, led to life-saving 
research into the effects of smoking.
More than two-thirds of deaths worldwide are in developing 
countries, yet little is known about the causes of death in 
these nations. In India, for example, just one-third of deaths 
are registered, and of these, only one-third provide data on 
the cause of death. India’s HIV/AIDS epidemic is rising—it may 
already have surpassed South Africa for the highest number of 
people infected. And like many other developing nations, the 
numbers of people dying from noncommunicable diseases such 
as heart disease and cancer are growing. Unlike most infectious 
diseases, the causes of noncommunicable ones can be the result 
of several risk factors, such as smoking, elevated blood pressure, 
or inherited genetic mutations.
With a population of 1 billion and growing, India urgently 
needs better data on the causes of death in its people if it is 
to take further steps to improve public health. To address this 
need, Prabhat Jha and colleagues designed a prospective study 
of 1 million deaths in India to run until 2014. They will monitor 
an expected 1 million deaths in nearly 14 million people across 
2.4 million households to ﬁ  nd patterns of disease according 
to gender, age, and region, and to better understand how risk 
factors such as tobacco and alcohol use and indoor air pollution 
are related to disease. 
The study uses one of India’s existing frameworks for 
measuring mortality, called the Sample Registration System 
Measuring Mortality in Developing Countries 
DOI: 10.1371/journal.pmed.0030056
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(SRS). At present, the system covers 50,000 deaths every year. 
Two independent workers visit the households; one visiting 
every month and the other every six months. Their reports are 
collated and any discrepancies reconciled by a third person. To 
improve the system, Jha and colleagues are using an innovative 
method called a “verbal autopsy” to record details of death 
as reported by family or friends to a trained but nonmedical 
ﬁ  eldworker. To ensure the robustness of the method, a random 
10% of the ﬁ  eldwork will be repeated by an independent audit 
team.
After validating the verbal autopsy method, the researchers 
began the ﬁ  rst phase of the study, which ran from 1998 to 
2003, and recorded deaths in 6.3 million people across 1.1 
million urban and rural households nationwide. As of November 
2005, the researchers have collected 140,000 verbal autopsy 
reports, and 35,000 have been coded and reconciled by two 
independent and trained physicians. They expect to record a 
total of about 300,000 deaths in the ﬁ  rst phase and 700,000 in 
the second phase in 2004–2014, which will look at 7.6 million 
people in 1.3 million households.
Better knowledge of genetic risk factors—about which little 
is known in developing or developed countries—requires 
collection of biological samples. Jha and colleagues are also 
planning to test the feasibility of this by collecting dried blood 
spots or tubes of blood in SRS units in four to ﬁ  ve Indian states. 
Studying mortality in 14 million people is a huge challenge, 
but one that is necessary in view of India’s vast population. As the 
researchers point out, direct measurement of the causes of death 
is a great deal more reliable than indirect estimation. By studying 
diseases that are common in one part of India but not in another, 
new risk factors should be discovered, and these are likely relevant 
worldwide. Mortality measurements will be key to the success of 
one of the world’s largest public health initiatives—the Millennium 
Development Goals, which were set in 2000 when countries 
worldwide pledged to reduce by half or more the incidence of 
many diseases in poor countries. We will only know whether these 
goals have been met if we have reliable mortality statistics.
Jha P, Gajalakshmi V, Gupta PC, Kumar R, Mony P, et al. (2006) 
Prospective study of 1 million deaths in India: Rationale, design, and 
validation results. DOI: 10.1371/journal.pmed.0030018
One-third of the world’s population 
is thought to be infected with 
Mycobacterium tuberculosis, the 
bacterium that causes tuberculosis. Yet, 
even though 2–3 million people die from 
tuberculosis every year, only 5%–10% of 
individuals infected with the causative 
agent ever become ill. Many factors affect 
how well a person’s immune system 
ﬁ  ghts off an attack by M. tuberculosis, 
including HIV infection, age, and 
malnutrition. It is also becoming clear 
that, as with other infectious diseases, 
host genetic factors affect susceptibility 
to tuberculosis.
One of the ﬁ  rst genes to be associated 
with susceptibility to tuberculosis was 
NRAMP1 (natural resistance-associated 
macrophage protein 1, now renamed 
SLC11A1). Others include the genes for 
the vitamin D receptor and the mannose 
receptor, and major histocompatibility 
complex (MHC) class II alleles. Variants of 
these genes, all of which encode proteins 
involved in the immune response, may 
affect how well the immune system deals 
with M. tuberculosis. 
Luis Barreiro, Lluis Quintana-Murci, 
and colleagues now report that two 
variants in the gene encoding another 
immune system molecule—DC-SIGN, 
which stands for dendritic cell–speciﬁ  c 
ICAM-3-grabbing nonintegrin—are 
linked to tuberculosis susceptibility. 
The ﬁ  rst rapid line of defense against 
M. tuberculosis and other pathogens 
is the innate immune system, where 
germline-encoded receptors recognize 
general features on pathogens. DC-SIGN, 
a C-type lectin that recognizes speciﬁ  c 
carbohydrate side chains present on 
the surface of pathogens, is the major 
receptor of this type for M. tuberculosis 
on human dendritic cells (immune 
system cells that process pathogens for 
presentation to the acquired immune 
system). Consequently, CD209—the gene 
encoding DC-SIGN—is a good place to 
search for genetic variants associated 
with tuberculosis susceptibility. 
The researchers looked for CD209 
gene variants in 351 individuals with 
tuberculosis and in 360 healthy controls 
living in the Cape Town area of South 
Africa. People living there are known 
as South African Colored and have a 
present-day uniform ethnicity. However, 
they derive genetically from populations 
of different ethnic backgrounds with 
different susceptibilities to tuberculosis. 
Due to the very high local incidence 
of tuberculosis, everyone living in this 
region, even healthy controls, is likely to 
have been exposed to M. tuberculosis. 
None of the participants were HIV-
positive. 
Barreiro and colleagues discovered two 
single-nucleotide polymorphisms (SNPs) 
or variants in CD209 whose frequency 
differed signiﬁ  cantly between healthy 
controls and people with tuberculosis. 
Both were in the promoter of CD209 
(promoters are noncoding regions that 
enable genes to be transcribed and 
proteins to be made). Variants −871G (a 
guanine 871 nucleotides upstream from 
the CD209 coding region) and −336A 
(an adenosine 336 nucleotides upstream 
from the coding region), either alone or 
in combination, were associated with 
decreased risk of developing tuberculosis 
in the study population. To make 
sure that these associations reﬂ  ected 
differences in disease susceptibility 
and not ethnic differences between 
the control and the diseased groups (a 
problem called population stratiﬁ  cation), 
the researchers showed that 25 other 
SNPs located genomewide had similar 
frequencies in both groups.
The researchers also report that 
the “protective” variants of CD209 are 
Variants in the DC-SIGN–Encoding Gene CD209 and Susceptibility to Tuberculosis
DOI: 10.1371/journal.pmed.0030061
DOI: 10.1371/journal.pmed.0030061.g001
False-color image of Mycobacterium 
tuberculosis
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more prevalent in Eurasians than in 
Africans—their presence in the South 
African Colored population likely 
reﬂ  ects the mixing of the two ethnic 
populations. They suggest that −871G 
and −336A may have been selected for 
in Europeans but not in Africans because 
tuberculosis has been endemic in Europe 
for several centuries, whereas in Africa 
it is thought to have arrived much more 
recently. However, because DC-SIGN is 
a receptor for many other pathogens, 
this geographical pattern of variants 
may reﬂ  ect exposure to other infectious 
agents besides M. tuberculosis. Indeed, 
genetic variation at position −336 of 
the CD209 promoter is associated with 
both the susceptibility to HIV and the 
severity of dengue fever. Whether 
it is the polymorphisms at positions 
−871 and −336 that directly affect host 
susceptibility (as opposed to other 
genetic variants of CD209 that these 
polymorphisms are closely linked to) is 
not entirely clear; nor is it known how 
the variants affect host susceptibility 
to infectious disease. One possibility is 
that they alter how much DC-SIGN is 
made (and results by others suggest 
that this is the case for at least one of the 
variants), which in turn could change 
the effectiveness of the host immune 
response. Knowing the functional 
consequences of the CD209 variants 
and the mechanisms by which they 
affect disease susceptibility, suggest the 
authors, should ultimately help in the 
development of new knowledge-based 
treatments for tuberculosis and other 
infectious diseases.
Barreiro LB, Neyrolles O, Babb CL, Tailleux 
L, Quch H, et al. (2006) Promoter variation 
in the DC-SIGN-encoding gene CD209 is 
associated with tuberculosis. DOI: 10.1371/
journal.pmed.0030020
Atherosclerosis, or hardening of the 
arteries, is the most common cause of 
death in industrialized countries. The 
formation in the arteries of deposits or 
plaques containing cholesterol, calcium, 
and other materials directly causes 
heart attacks, strokes, and peripheral 
circulatory problems by blocking the 
blood ﬂ  ow to the heart, brain, or limbs, 
respectively. In addition, plaque rupture 
causes the formation of blood clots, 
which can block arterial blood ﬂ  ow 
anywhere in the body.
Major risk factors for atherosclerosis 
include high blood pressure, obesity, 
smoking, and levels of certain 
cholesterol-containing particles in the 
blood stream. Cholesterol is carried 
around the body by particles called 
lipoproteins, molecules that include 
both lipids (fats) and proteins. Low-
density lipoprotein (LDL) particles 
transport cholesterol to the arteries 
and other tissues that take up lipids. 
High blood concentrations of LDL 
particles are associated with high risk of 
atherosclerosis; the cholesterol carried 
by LDL (LDL-C) is “bad” cholesterol. By 
contrast, high concentrations of high-
density lipoprotein (HDL) particles 
protect against cardiovascular disease 
by removing cholesterol from the 
arteries and taking it to the liver for 
excretion. Consequently, cholesterol 
carried by HDL (HDL-C) is “good” 
cholesterol, and individuals with high 
plasma concentrations of HDL-C and low 
concentrations of LDL-C are at lowest risk 
for cardiovascular disease.
Enzymes known as lipases modulate 
lipoprotein metabolism, and the activity 
of two of them—lipoprotein lipase and 
hepatic lipase—is known to affect the risk 
of atherosclerosis. Karen Badellino and 
colleagues are investigating whether a 
third lipase—endothelial lipase (EL)—
also affects atherosclerosis risk in people, 
since this enzyme digests HDL and affects 
the development of atherosclerosis in 
mouse models. 
Badellino and colleagues have used a 
new immunoassay to measure plasma EL 
concentrations in 858 unrelated people 
enrolled in the Study of Inherited Risk of 
Atherosclerosis, a cross-sectional study 
designed to investigate biomarkers and 
genetic factors associated with coronary 
atherosclerosis. Participants, who were 
just examined once rather than followed 
over time, as happens in a prospective, 
longitudinal study, had a family history 
of premature coronary artery disease 
(CAD) but were asymptomatic and had 
no other major risk factors for CAD. 
Because EL is normally bound tightly 
to heparin and is largely unavailable 
for immunoassay, the authors also 
measured EL concentrations in 510 
individuals after heparin treatment to 
get an accurate measure of total EL 
mass. They then checked whether pre 
and postheparin EL levels were linked 
in any way to the concentrations of 
speciﬁ  c lipoproteins, components of 
the metabolic syndrome (a syndrome 
associated with cardiovascular disease 
that includes high blood pressure 
and obesity), or coronary arterial 
calciﬁ  cation, a noninvasive measure of 
early coronary atherosclerosis.
The researchers found that although 
the average postheparin concentration 
of EL was about three times the average 
preheparin concentration, pre and 
postheparin levels in individuals were 
strongly correlated. This result suggests 
that measurements of EL levels in 
untreated individuals will provide a 
good indication of the total vascular 
Endothelial Lipase: A New Risk Factor for Atherosclerosis?
DOI: 10.1371/journal.pmed.0030054
DOI: 10.1371/journal.pmed.0030054.g001
Endothelial lipase and atherosclerosis
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expression of EL for future studies. 
Then, they discovered that EL plasma 
levels both before and after heparin 
treatment correlated positively with 
components of the metabolic syndrome. 
Furthermore, as in mice, high levels of 
EL correlated with low levels of HDL-C, 
or “good” cholesterol. This last inverse 
association was small but statistically 
signiﬁ  cant, as was the positive 
association between EL concentrations 
and signs of early atherosclerosis, even 
after taking into account other risk 
factors for atherosclerosis.
Overall, the authors suggest that EL 
is a proatherogenic factor in people, 
particularly those with metabolic 
syndrome. EL concentrations, 
they suggest, may modulate the 
composition of lipoproteins in the 
blood and thus atherosclerosis risk. 
But, they note, only prospective, 
longitudinal studies in which EL 
concentrations are correlated with 
subsequent heart attacks, strokes, and 
other cardiovascular problems can 
show whether EL concentration really 
is a risk factor for atherosclerosis, and 
thus whether interventions designed 
to reduce EL activity can prevent 
atherosclerosis.
Badellino KO, Wolfe MG, Reilly MP, Rader 
DJ (2006) Endothelial lipase concentrations 
are increased in metabolic syndrome and 
associated with coronary atherosclerosis. 
DOI: 10.1371/journal.pmed.0030022
West Nile virus (WNV) was ﬁ  rst isolated 
in 1937 from a sick woman living in the 
West Nile District of Uganda. Since then, 
it has been found in other parts of Africa, 
Europe, the Middle East, and central Asia, 
as well as around the Paciﬁ  c. Then in 
1999, it arrived in the Queens borough of 
New York City. During this ﬁ  rst season, it 
caused 62 cases of encephalitis and seven 
deaths. WNV has since then spread across 
the United States, and can now be found 
in most states.
WNV is a ﬂ  avivirus, a type of RNA virus. 
Like many other ﬂ  aviviruses, including 
the dengue and yellow fever viruses, 
WNV is a blood-borne virus that is passed 
to people through mosquito bites; in the 
case of WNV, the mosquitoes acquire the 
virus predominantly by biting infected 
birds. Most people infected with WNV 
have no symptoms, but 20% of them 
develop West Nile fever, a ﬂ  u-like disease. 
About 1% of infected individuals—
usually older people or those with a 
weak immune system—develop severe 
neuroinvasive disease, either encephalitis 
or meningitis, which can cause long-term 
health problems or death. In 2005, about 
100 people in the US died after infection 
with WNV.
Virtually all WNV transmission is 
through mosquito bites, but a few cases 
of WNV infection, some of them fatal, 
have been linked to contaminated blood 
transfusions. Consequently, in 2004, the 
US Food and Drug Administration (FDA) 
mandated that blood donations must 
be screened for WNV. The FDA did not 
recommend a speciﬁ  c screening method. 
In an ideal world, screening would aim 
to reduce the risk of contracting WNV 
from a blood transfusion as much as 
possible, at any cost. In the real world, 
however, the health beneﬁ  ts of any 
screening methodology (lives saved 
and improvements in the quality of life) 
have to be balanced against the costs of 
screening. To ﬁ  nd out where this balance 
lies for WNV, Caroline Korves, Sue Goldie, 
and Megan Murray have estimated the 
cost-effectiveness of different strategies 
for screening blood donations for WNV 
and now report their results.
The researchers used a computer-
based mathematical model to 
compare different screening strategies. 
The baseline strategy was a donor 
questionnaire—blood donors reporting 
a recent fever cannot donate blood. The 
other strategies tested were nucleic acid 
testing of pools or individual samples 
of blood for WNV, universal screening 
versus screening restricted to donations 
destined for immunocompromised 
recipients, and seasonal screening 
versus screening throughout the 
year (WNV transmission peaks in late 
summer/early fall). The researchers 
modeled the cost-effectiveness of these 
strategies in areas with high levels of 
WNV transmission over a long season 
(as occurred in Mississippi in 2002), 
high transmission over a short season 
(Nebraska 2002), and low transmission 
over a short season (Massachusetts 
2002).
Korves and colleagues found that 
in low-transmission areas with a short 
season, screening by questionnaire 
alone was the most cost-effective 
strategy—any other strategy was 
unlikely to prevent any cases of serious 
illness despite greatly increasing 
costs. In areas with high transmission, 
the best approach was seasonal 
screening by nucleic acid testing of 
individual donations earmarked for 
immunocompromised recipients. The 
researchers also discovered that seasonal 
screening of all donations provided 
little additional clinical beneﬁ  t and 
was prohibitively expensive, and that 
screening throughout the year provided 
no additional beneﬁ  t in any setting.
These results indicate that the 
currently mandated policy of screening 
donated blood for WNV may not be 
the best public health strategy. More 
restricted screening strategies may be 
preferable, suggest the investigators, 
with individual states adopting 
screening strategies that reﬂ  ect the 
intensity and duration of their West 
Nile epidemics. The researchers also 
note that their estimates of the cost 
of WNV blood screening strategies 
were greater than generally accepted 
cost-effectiveness thresholds for health 
interventions. Thus, the resources 
spent in preventing rare cases of WNV 
infection arising from blood transfusion 
might be better used to reduce WNV 
transmission through controlling 
mosquito vectors. If such an approach 
were successful, they suggest, it might 
obviate the need for screening blood for 
WNV in many areas.
Korves CT, Goldie SJ, Murray MB (2006) 
Cost-effectiveness of alternative blood 
screening strategies for West Nile virus in 
the United States. DOI: 10.1371/journal.
pmed.0030021
The Cost of Screening Blood Donations for West Nile Virus
DOI: 10.1371/journal.pmed.0030062 
DOI: 10.1371/journal.pmed.0030062.g001
A number of mosquito species can transmit 
WNV, including Aedes japonicus, depicted 
here
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ill (four out of seven patients). In 25 
patients who died more than two weeks 
after the onset of symptoms (generally 
high temperature and lower respiratory 
tract symptoms, followed by pneumonia), 
there was no SARS-CoV in post-mortem 
lung tissue, although in one case the 
virus had been present in an open lung 
biopsy taken ﬁ  ve days after disease 
onset. The researchers found no virus in 
tissues other than the lung in any of the 
patients, but in the four patients whose 
lungs contained SARS-CoV, the virus was 
found in pneumocytes—cells that line 
the alveoli, the terminal air spaces where 
gas exchange occurs—and sometimes 
in alveolar macrophages, a type of 
immune cell. No SARS-CoV was found in 
the cells lining the tubes leading to the 
alveoli, which explains why patients with 
SARS only have lower respiratory tract 
symptoms. 
These results indicate that the human 
immune system can stop SARS-CoV 
replicating within two weeks of infection. 
By that time, however, the damage to 
the lungs in some patients appears to 
be so great that they die even without 
continued viral replication. This time 
course of events indicates that antiviral 
drugs are likely to be useful only during 
the early stages of SARS. In addition, 
the absence of virus outside the lungs 
suggests that death is the result of 
SARS-CoV replicating in the lungs alone. 
Whether SARS-CoV fatally damages lung 
tissue directly or whether macrophages 
recruited to the lungs in response to 
infection with SARS-CoV cause fatal 
immunopathological changes remains an 
open question.
Nicholls JM, Butany J, Poon LLM, Chan 
KH, Beh SL, et al. (2006) Time course 
and cellular localization of SARS-CoV 
nucleoprotein and RNA in lungs from fatal 
cases of SARS. DOI: 10.1371/journal.
pmed.0030027
It is widely believed that racial and 
ethnic minority groups, especially in the 
US, are less willing to participate in health 
research than non-minority groups. 
According to this view, minority groups’ 
comparative unwillingness to participate 
is due to a lack of trust in health research 
and health researchers, which traces to 
past abuses, particularly the Tuskegee 
Syphilis Study. Conducted from 
1932–1972, the US government–funded 
Tuskegee study examined the natural 
course of syphilis. The participants, 399 
African-American men in the late stages 
of syphilis, were enrolled and offered free 
medical care but kept in the dark about 
the nature of their illness and the purpose 
of the study. Participants were told that 
they were being treated for “bad blood,” 
but the doctors had no intention of 
curing them and even withheld penicillin 
treatment when it became available. 
When the experiment was ﬁ  nally 
ended—after public outcry following 
exposure in the media—28 of the men 
had died directly of syphilis, 100 were 
suffering from related complications, 40 
of their wives had become infected, and 
19 of their children had been born with 
congenital syphilis. 
Given that the study was not halted 
until 1972, it would not be surprising 
if its memory inﬂ  uenced the attitudes 
of minority individuals toward health 
research today. This is a potential 
problem, because it is essential that 
participants in health research are as 
diverse as the population whose health 
should be improved as a result of the 
research. (And in the US today, one in ﬁ  ve 
people is from a minority group). Only 
representative participation ensures that 
the outcomes of health research can be 
generalized to a diverse population. 
Is participation in health research 
representative of the population? A 
number of studies suggest that in the 
US it is not; minority groups are often 
Minority Participation in Health Research—Facts and Fiction
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Severe acute respiratory syndrome 
(SARS) ﬁ  rst emerged in Guangdong 
Province, China, in November 2002. At 
the end of February 2003, an infected 
doctor from the province inadvertently 
took the illness to Hong Kong. From 
there, a woman staying in the same 
hotel contracted the disease and took 
it back with her when she returned to 
Toronto, Canada. SARS, with its ability 
to spread by close person-to-person 
contact and with its 10% death rate, was 
on the move and was threatening to 
cause a worldwide epidemic. The World 
Health Organization responded rapidly 
to this threat by issuing a global alert, 
and warning against unnecessary travel 
to affected areas. This and rigorous local 
containment efforts meant that only 
8,098 people became ill, and only 774 
people died in this ﬁ  rst SARS epidemic.
The last case of the epidemic was 
reported in Taiwan in June 2003, and 
since then there have only been a few 
isolated cases. But the coronavirus 
responsible for SARS (SARS-CoV) could 
cause another epidemic at any time. 
Consequently, scientists continue 
to study SARS intensively, including 
researchers from Hong Kong and 
Toronto, who have joined forces to 
examine the organs of people who died 
from SARS in these two cities and now 
report their results. As John Nicholls, the 
leader of the international team, explains, 
understanding how the SARS virus kills 
people should help in the treatment of 
SARS if it re-emerges.
Nicholls and colleagues collected 
post-mortem material from 32 fatal 
cases of SARS (the largest such collection 
to date), and asked three questions 
about the pathogenesis of SARS. First, 
was SARS-CoV present in the lungs 
of these patients throughout their 
illness? Second, which cells in the 
lungs contained the virus? Third, did 
any other tissues contain SARS-CoV? 
The researchers used three molecular 
techniques to look for SARS-CoV in their 
specimens: immunohistochemistry, 
which detects virus-speciﬁ  c proteins; 
in situ hybridization, which detects the 
viral genome; and reverse-transcriptase 
polymerase chain reaction (RT-PCR), 
which measures viral load.
The researchers found that SARS-CoV 
was present only in the lungs of patients 
who died within two weeks of becoming 
Pathological Clues to How the SARS Virus Kills
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under-represented in US research studies. 
But what are the reasons? Are minority 
groups less willing to participate, or 
are they given fewer opportunities to 
participate? Answering this question 
is vital for efforts to increase minority 
participation in health research. Should 
these efforts focus on changing minority 
attitudes or on removing potential 
barriers to participation, such as whether 
minorities are adequately informed of 
research opportunities?
In a systematic review in this 
month’s PLoS Medicine, David Wendler 
and colleagues assessed whether 
individuals from minority groups who 
were eligible and invited to participate 
in health research were indeed less 
likely to consent to participate than 
non-minority individuals. The authors 
identiﬁ  ed 20 health research studies 
that reported consent rates by race 
or ethnicity. Eighteen were single-site 
studies conducted exclusively in the US 
or multi-site studies conducted primarily 
or exclusively in the US. The 20 studies 
collectively report the enrollment 
decisions of over 70,000 individuals for a 
broad range of health research studies.
For the three non-intervention studies, 
African-Americans had a non-signiﬁ  cantly 
lower overall consent rate than non-
Hispanic whites, while Hispanics had a 
non-signiﬁ  cantly higher overall consent 
rate than non-Hispanic whites. For 
the ten intervention studies, African 
Americans’ overall consent rate was 
non-signiﬁ  cantly higher than that of 
non-Hispanic whites, while Hispanics had 
a statistically signiﬁ  cant higher overall 
consent rate than non-Hispanic whites. 
For the seven surgery trials, minorities as 
a group had a non-signiﬁ  cantly higher 
overall consent rate than non-Hispanic 
whites. 
Although Wendler and colleagues 
found only small differences in consent 
rates by race or ethnicity, they found 
substantial differences by race or 
ethnicity in the number of individuals 
invited to participate. For example, 
one study of medical versus surgical 
management of angina offered 
enrollment to 2,065 non-Hispanic whites 
but to only 30 individuals from minority 
groups.
This study, Wendler and colleagues 
say, “suggests that racial and ethnic 
minorities are as willing as non-Hispanic 
whites to participate in health research.” 
Indeed for some kinds of studies, 
minority individuals seem more willing 
to enroll than non-minority individuals. 
The authors acknowledge their study’s 
limitations, particularly the fact that 
most individuals were from the US 
and the willingness of minority groups 
outside the US to participate in health 
research may be very different. Other 
important questions not addressed by 
this study are what motivates people 
to participate in health research, 
and whether motives differ between 
majority and minority groups. Despite 
these and other remaining questions, 
the results of this study suggest that 
efforts to increase minority participation 
in health research should concentrate 
on ensuring better access to health 
research for all groups, rather than 
on changing the attitudes of minority 
groups.
Wendler D, Kington R, Madans J, Van 
Wye G, Christ-Schmidt H, et al. (2006) Are 
racial and ethnic minorities less willing 
to participate in health research? DOI: 
10.1371/journal.pmed.0030019
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